0001437749-24-023017.txt : 20240718
0001437749-24-023017.hdr.sgml : 20240718
20240718185718
ACCESSION NUMBER: 0001437749-24-023017
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240717
FILED AS OF DATE: 20240718
DATE AS OF CHANGE: 20240718
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: HUNT DOUGLAS M
CENTRAL INDEX KEY: 0001727172
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35703
FILM NUMBER: 241125744
MAIL ADDRESS:
STREET 1: C/O PUMA BIOTECHNOLOGY,INC.
STREET 2: 10880 WILSHIRE BOULEVARD, SUITE 2150
CITY: LOS ANGELES
STATE: CA
ZIP: 90024
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PUMA BIOTECHNOLOGY, INC.
CENTRAL INDEX KEY: 0001401667
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 770683487
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10880 WILSHIRE BLVD.
STREET 2: SUITE 2150
CITY: LOS ANGELES
STATE: CA
ZIP: 90024
BUSINESS PHONE: (424) 248-6500
MAIL ADDRESS:
STREET 1: 10880 WILSHIRE BLVD.
STREET 2: SUITE 2150
CITY: LOS ANGELES
STATE: CA
ZIP: 90024
FORMER COMPANY:
FORMER CONFORMED NAME: INNOVATIVE ACQUISITIONS CORP
DATE OF NAME CHANGE: 20070601
4
1
rdgdoc.xml
FORM 4
X0508
4
2024-07-17
0001401667
PUMA BIOTECHNOLOGY, INC.
PBYI
0001727172
HUNT DOUGLAS M
C/O PUMA BIOTECHNOLOGY, INC.
10880 WILSHIRE BLVD., SUITE 2150
LOS ANGELES
CA
90024
1
See Remarks
1
Common Stock
2024-07-17
4
S
0
3637
3.70110
D
133227
D
Adoption date of referenced 10b5-1(c) sell to cover program is: 12-14-2020.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.6001 to $3.8901, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The Reporting Person is the Senior Vice President of Regulatory Affairs of the Issuer.
/s/ Gordon Esplin as attorney-in-fact for Douglas M. Hunt
2024-07-18